Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

NCT04732494 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

BIOLOGICAL: Tislelizumab
BIOLOGICAL: Ociperlimab
DRUG: Placebo

Sponsor

BeiGene